Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERASNASDAQ:SIGANASDAQ:SLSNASDAQ:TRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.16-4.1%$1.52$1.04▼$3.45$328.59M1.221.79 million shs3.21 million shsSIGASIGA Technologies$5.39+3.3%$5.77$4.95▼$12.83$372.90M1.03777,423 shs487,507 shsSLSSELLAS Life Sciences Group$1.04-5.5%$1.23$0.77▼$1.84$99.93M2.531.37 million shs1.32 million shsTRMLTourmaline Bio$12.83-2.2%$14.87$11.87▼$29.79$329.54M2.35277,578 shs295,343 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca-4.13%-23.68%-18.31%-57.66%-46.54%SIGASIGA Technologies+3.26%-2.88%-1.46%-14.85%-45.61%SLSSELLAS Life Sciences Group-5.45%-6.31%-15.45%-3.70%-20.61%TRMLTourmaline Bio-2.21%-22.94%-0.54%-40.13%-41.42%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca3.7095 of 5 stars4.51.00.00.03.83.31.3SIGASIGA Technologies2.5483 of 5 stars0.03.00.00.03.50.83.1SLSSELLAS Life Sciences Group0.0693 of 5 stars0.02.00.00.00.00.00.6TRMLTourmaline Bio1.7747 of 5 stars3.51.00.00.02.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.83316.67% UpsideSIGASIGA Technologies 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 0.00N/AN/AN/ATRMLTourmaline Bio 3.00Buy$45.20252.30% UpsideCurrent Analyst Ratings BreakdownLatest SLS, SIGA, TRML, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025ERASErascaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/21/2025ERASErascaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.003/21/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/14/2025TRMLTourmaline BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $43.003/14/2025TRMLTourmaline BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$49.00 ➝ $50.003/7/2025ERASErascaMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$4.00 ➝ $4.003/6/2025TRMLTourmaline BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$42.002/24/2025TRMLTourmaline BioLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$58.001/7/2025ERASErascaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.00 ➝ $5.00(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$2.10 per shareN/ASIGASIGA Technologies$138.72M2.78$0.85 per share6.34$2.77 per share1.95SLSSELLAS Life Sciences Group$1M94.48N/AN/A($0.25) per share-4.16TRMLTourmaline BioN/AN/AN/AN/A$10.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$125.04M-$0.74N/AN/AN/AN/A-42.26%-34.97%5/14/2025 (Estimated)SIGASIGA Technologies$68.07M$0.824.494.31N/A49.33%49.06%38.72%5/6/2025 (Estimated)SLSSELLAS Life Sciences Group-$37.34M-$0.52N/AN/AN/AN/A-629.46%-178.65%5/13/2025 (Estimated)TRMLTourmaline Bio-$42.12M-$2.87N/AN/AN/AN/A-20.97%-20.56%5/12/2025 (Estimated)Latest SLS, SIGA, TRML, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2025Q4 2024ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A3/20/2025Q4 2024SLSSELLAS Life Sciences Group-$0.1067-$0.08+$0.0267-$0.08N/AN/A3/13/2025Q4 2024TRMLTourmaline Bio-$0.91-$0.86+$0.05-$0.86N/A$0.04 million3/11/2025Q4 2024SIGASIGA TechnologiesN/A$0.63N/A$0.63N/A$81.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/ASIGASIGA TechnologiesN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A11.0011.00SIGASIGA TechnologiesN/A8.105.32SLSSELLAS Life Sciences GroupN/A2.262.26TRMLTourmaline BioN/A40.3340.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%SIGASIGA Technologies55.40%SLSSELLAS Life Sciences Group17.38%TRMLTourmaline Bio91.89%Insider OwnershipCompanyInsider OwnershipERASErasca21.50%SIGASIGA Technologies1.54%SLSSELLAS Life Sciences Group1.20%TRMLTourmaline Bio11.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.27 million221.94 millionOptionableSIGASIGA Technologies4071.44 million70.31 millionOptionableSLSSELLAS Life Sciences Group1090.85 million69.54 millionNot OptionableTRMLTourmaline Bio4425.69 million22.82 millionOptionableSLS, SIGA, TRML, and ERAS HeadlinesRecent News About These CompaniesPictet Asset Management Holding SA Boosts Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)April 4 at 3:55 AM | marketbeat.comTourmaline Bio: We Should Wait For Upcoming Phase 2b Trial DataApril 3 at 5:57 PM | seekingalpha.comTruist biotech analyst holds an analyst/industry conference callApril 2 at 11:00 AM | markets.businessinsider.comSwiss National Bank Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML)March 31, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of "Buy" by AnalystsMarch 16, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Given New $43.00 Price Target at WedbushMarch 15, 2025 | marketbeat.comTOURMALINE BIO Earnings Results: $TRML Reports Quarterly EarningsMarch 15, 2025 | nasdaq.comTourmaline Bio (TRML) Gets a Buy from WedbushMarch 15, 2025 | markets.businessinsider.comTourmaline Bio (NASDAQ:TRML) Stock Price Expected to Rise, HC Wainwright Analyst SaysMarch 15, 2025 | marketbeat.comTourmaline Bio price target raised to $43 from $42 at WedbushMarch 14, 2025 | markets.businessinsider.comTourmaline Bio (NASDAQ:TRML) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPSMarch 14, 2025 | marketbeat.comTourmaline Bio, Inc.: Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 14, 2025 | finanznachrichten.deTourmaline Bio reports Q4 EPS (86c), consensus (87c)March 14, 2025 | markets.businessinsider.comTourmaline Bio shares fall as Q4 loss widensMarch 14, 2025 | investing.comTourmaline Bio sees cash runway into 2H27March 14, 2025 | markets.businessinsider.comTourmaline Bio’s 2024 Financial Results and Strategic AdvancesMarch 14, 2025 | tipranks.comTourmaline Bio, Inc. Announces Over-Enrolled Phase 2 TRANQUILITY Trial and Strengthens Cardiovascular Scientific Advisory Board Amid Positive Financial OutlookMarch 13, 2025 | quiverquant.comTourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 13, 2025 | globenewswire.comTourmaline Bio (TRML) Projected to Post Earnings on TuesdayMarch 11, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Tourmaline Bio (TRML)March 10, 2025 | markets.businessinsider.comWedbush Forecasts Tourmaline Bio FY2024 EarningsMarch 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLS, SIGA, TRML, and ERAS Company DescriptionsErasca NASDAQ:ERAS$1.16 -0.05 (-4.13%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$1.19 +0.03 (+2.59%) As of 04/4/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.SIGA Technologies NASDAQ:SIGA$5.39 +0.17 (+3.26%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$5.28 -0.11 (-2.13%) As of 04/4/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.SELLAS Life Sciences Group NASDAQ:SLS$1.04 -0.06 (-5.45%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$1.05 +0.01 (+0.87%) As of 04/4/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Tourmaline Bio NASDAQ:TRML$12.83 -0.29 (-2.21%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$12.83 0.00 (0.00%) As of 04/4/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
